Prosthesis and Surgery Guide System for Personalized Total Knee Arthroplasty

NCT ID: NCT04963491

Last Updated: 2021-07-15

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-01
• Study Completion Date: 2023-08-31

Brief Summary

The subject is planned to carry out the clinical trails of femoral condyle prosthesis, tibial tray prosthesis and meniscus prosthesis; At the same time, in order to achieve personalized precision bone resection, the clinical trial verification is carried out on the personalized cutting guides.

Detailed Description

The subject continues the research of Professor Jia-kuo Yu's research group on the personalized design, processing and manufacturing of personalized total knee arthroplasty (TKA) prostheses and the verification of animal and human cadavers. It is planned to carry out the clinical trails of femoral condyle prosthesis, tibial tray prosthesis and meniscus prosthesis; At the same time, in order to achieve personalized precision bone resection, the clinical trial verification is carried out on the personalized cutting guides.

In the clinical validation study, the research team will summarize the role of personalized TKA prostheses and personalized TKA cutting guides in the precise and minimally invasive treatment of knee osteoarthritis.

Conditions

Knee Osteoarthritis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

3D printed personalized TKA prosthesis

Design：Personalized TKA prosthesis Manufacture：3D

Group Type: EXPERIMENTAL

Personalized TKA prosthesis

Intervention Type: DEVICE

TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy

Zimmer NexGen TKA prostheses

Prosthesis has been widely used in clinic

Group Type: ACTIVE_COMPARATOR

Zimmer NexGen prostheses

Intervention Type: DEVICE

Commercial products used on a large scale

Interventions

Personalized TKA prosthesis

TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy

Intervention Type: DEVICE

Zimmer NexGen prostheses

Commercial products used on a large scale

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Degenerative osteoarthritis, traumatic arthritis or avascular necrosis, inflammatory joint disease and other end-stage knee joint diseases, as well as the correction of deformities, reconstruction after failure of some knee joint prostheses, and other techniques that cannot be handled In the case of fractures, total knee prosthesis replacement is required.

2. Age ≥50, ≤80 years old.

3. The subject or guardian is willing and able to sign an informed consent form.

Exclusion Criteria

1. History of previous knee surgery.

2. Severe knee joint deformity (valgus greater than 15° or valgus greater than 20°) or knee joint instability;

3. Severe flexion contracture deformity (flexion contracture> 25°);

4. Perform total knee joint revision and replacement surgery;

5. Rheumatoid arthritis;

6. Body Mass Index (BMI) > 35.

7. Patients with neuromuscular insufficiency (for example, paralysis, myolysis or muscle weakness) can lead to postoperative knee instability or abnormal gait;

8. Pregnant or lactating women;

9. Suffer from the underlying medical condition (including but not limited to metabolism, hematology, kidney, liver, lung, nerve, endocrine, heart, infection or gastrointestinal tract) that the researcher believes that the patient is at an unacceptable risk; Serious progressive or uncontrolled diseases that are not suitable for trials or put them at high risk, including any medical or psychiatric conditions that the investigator believes will prevent subjects from following the protocol or completing the study according to the protocol.

10. Being infected with human immunodeficiency virus (HIV), infectious hepatitis B or hepatitis C, or a corresponding medical history.

11. Suffer from a progressive infection or malignant disease, and be able to provide chest X-ray, computed tomography (CT scan) or MRI evidence within 12 weeks before screening, and be verified by a qualified physician.

12. Active systemic infections (except colds) or any other infections that will recur regularly during the previous two weeks.

13. There is a history of chronic or recurrent infectious diseases, or evidence of tuberculosis infection that was judged to be positive at the time of screening. Subjects who have obtained positive or uncertain results can participate in the study if they have undergone a comprehensive tuberculosis examination (according to local practice/guidelines) within 12 weeks before baseline and finally confirmed that there is no evidence of active tuberculosis. If the presence of latent tuberculosis is confirmed, treatment must be initiated and maintained in accordance with local or national guidelines before the baseline.

14. History of lymphoproliferative disease, or any known malignant tumor, or history of malignant tumor of any organ system in the past 5 years (Bowen's disease, basal cell carcinoma, or actinic keratosis after treatment and no evidence of recurrence in the past 12 weeks Except for diseases; except for excised cervical carcinoma in situ or non-invasive malignant colon polyps).

15. At the same time suffering from medical problems, including but not limited to the following:

16. Uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥95mmHg), congestive heart failure (New York Heart Association status classification III or IV).

17. Subjects with a serum creatinine level exceeding 2.0 mg/dl (176.8 μmol/L).

18. Total white blood cell (WBC) count at screening <2500/μL, or platelet <100000/μL or neutrophil <1500/μL or hemoglobin <8.5 g/dL.

19. In the six months before the baseline, there is a history of alcohol or drug abuse or evidence of ongoing abuse.

20. The patient is mentally incapable or unable to understand the requirements for participating in the research.

• Minimum Eligible Age: 51 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Inner Mongolia People's Hospital

OTHER

Sponsor Role: collaborator

Jining Medical University

OTHER

Sponsor Role: collaborator

Peking University Third Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jia-kuo Yu

Role: STUDY_DIRECTOR

Peking University Third Hospital

Central Contacts

Fu-zhen Yuan

Role: CONTACT

yuanfuzhen2016@163.com

18511440808

Other Identifiers

M2020518

Identifier Type: -

Identifier Source: org_study_id